Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma
07 janv. 2019 08h30 HE
|
Cellectar Biosciences, Inc.
FLORHAM PARK, N.J., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Cellectar Biosciences to Present at the Biotech Showcase
03 janv. 2019 08h30 HE
|
Cellectar Biosciences, Inc.
FLORHAM PARK, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Cellectar Granted Japanese Patent for CLR 131
11 déc. 2018 08h30 HE
|
Cellectar Biosciences, Inc.
FLORHAM PARK, N.J., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma
04 déc. 2018 08h30 HE
|
Cellectar Biosciences, Inc.
FLORHAM PARK, N.J., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update
13 nov. 2018 08h30 HE
|
Cellectar Biosciences, Inc.
FLORHAM PARK, N.J., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (“Cellectar” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery,...
Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies
12 nov. 2018 08h30 HE
|
Cellectar Biosciences, Inc.
Clinical Trials to Advance Across Multiple Hematology Programs FLORHAM PARK, N.J., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical...
Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma
02 oct. 2018 08h00 HE
|
Cellectar Biosciences, Inc.
MADISON, Wis., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference
27 sept. 2018 08h30 HE
|
Cellectar Biosciences, Inc.
MADISON, Wis., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma
25 sept. 2018 08h30 HE
|
Cellectar Biosciences, Inc.
MADISON, Wis., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
Cellectar Biosciences Provides an Update on the FDA Import Alert
24 sept. 2018 08h00 HE
|
Cellectar Biosciences, Inc.
MADISON, Wis., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...